SOURCE: BASi (Bioanalytical Systems, Inc.)

February 16, 2006 09:56 ET

BASi and INCAPS Enter Corporate Alliance

INDIANAPOLIS, IN -- (MARKET WIRE) -- February 16, 2006 --INCAPS (Indianapolis) and BASi (West Lafayette) (NASDAQ: BASI) have announced a corporate alliance whereby the two contract research organizations will offer complementary services. INCAPS has a focus on proteomics and protein characterization studies using current and emerging technology platforms. BASi is focused on in-life safety and pharmacology assessment of new drug substances with a small molecule focus.

BASi Chairman and CEO Pete Kissinger commented, "INCAPS has assembled a first-rate team and state-of-the-art instrumentation, informatics and statistical analysis tailored toward discovery biology and biomarkers. This is an increasingly important part of what our clients require, and it is more advantageous for us to partner rather than add these resources to our own business. The geographic proximity of INCAPS to both our West Lafayette and Evansville laboratories is convenient, and we already have several common clients. This alliance is especially important for us because there is increased interest in monitoring the safety and effectiveness of drugs by examining proteomic responses to chronic and acute dosing. It's all about understanding metabolic mechanisms."

Dr. James Ludwig, CEO of INCAPS added, "We are pleased to be able to offer our clients one-stop shopping for large- and small-molecule work. BASi has established themselves as a leader in bioanalytical chemistry services and we are delighted to be associated with them."

About BASi

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new drugs to market. Visit for more about BASi.


INCAPS, a BioCrossroads Company, is a fee-for-service contract research organization with expertise in protein analysis, proteomics, technology validation and biomarker collaborations. The Company offers multiple, state-of-the-art, mass spectrometry technologies coupled with proprietary sample preparation methods and quantification software. INCAPS provides a secure and confidential environment, and clients own all of the data generated. More information about INCAPS is available at

Contact Information

    Edward M. Chait
    Email Contact